The UK has had a pneumococcal polysaccharide vaccination (PPV) programme for groups
at higher risk of invasive disease since 1992. This paper presents data from a sample of …

Objective Following the licensure of 23-valent pneumococcal polysaccharide vaccine
(23vPPV) in 1989, a risk-group–only immunization policy was implemented in 1992 in …

Over the last decade, there has been no discernible reduction in Invasive Pneumococcal
Disease (IPD) amongst Indigenous adults in the Northern Territory (NT) of Australia, despite …

Abstract Background Although nearly all Australian children are vaccinated against
pneumococcal disease, pneumococcal vaccine uptake is low among high-risk adults. This …

Introduction of pneumococcal conjugate and polysaccharide vaccines into the United
Kingdom's routine immunization programmes is expected to change the epidemiology of …

Since April 2014, invasive pneumococcal disease incidence has increased substantially
across North East England, United Kingdom, reversing the decline that followed the 2006 …

Background Indigenous adults residing in the Northern Territory of Australia experience
elevated rates of invasive pneumococcal disease despite the routine use of 23-valent …

The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for all
aged⩾ 65 years in the UK to help reduce the burden of invasive pneumococcal disease …

Abstract Background For winter 2003/2004 in Scotland, it was recommended that all those
aged 65 and over be eligible to receive 23-valent polysaccharide pneumococcal vaccine …

Background In the UK certain groups with pre-disposing conditions are eligible for
vaccination with the pneumococcal polysaccharide vaccine (PPV23). Uptake of the vaccine …